Porter P L, Garcia R, Moe R, Corwin D J, Gown A M
Department of Pathology, University of Washington, Seattle 98195.
Cancer. 1991 Jul 15;68(2):331-4. doi: 10.1002/1097-0142(19910715)68:2<331::aid-cncr2820680221>3.0.co;2-x.
Lobular carcinoma in situ (LCIS) has uncertain malignant potential; biologic markers that will identify patients at risk for a poor clinical outcome have been sought actively. Amplification of the c-erbB-2 protooncogene has been correlated with poor prognosis in invasive mammary carcinoma, and immunohistochemical evaluation for expression of the oncogene protein has been correlated with gene amplification. The authors retrospectively evaluated 62 cases of lobular neoplasia for expression of the c-erbB-2 gene product on formalin-fixed, deparaffinized sections, using two monoclonal anti-erbB-2 (p185) antibodies (c-neu Ab3 and m-erb) and one polyclonal anti-erbB-2 antibody (pAb 1) by the avidin-biotin-peroxidase method. All 62 cases were negative with the pAb 1 antibody; one of 62 cases was weakly positive with the c-neu Ab3 in a membranous pattern. Expression of c-erbB-2 gene product was identified on adjacent invasive ductal carcinoma in one case and in adjacent ductal carcinoma in situ in another. None of 15 cases if infiltrating lobular carcinoma was positive with either of the two anti-c-erbB-2 antibodies. Strong positivity was found on benign epithelium in one case, demonstrating epitheliosis. In summary, evidence of expression of the c-erbB-2 gene product was found in one of 57 cases of LCIS and none of 15 cases of invasive lobular carcinoma. This suggests that, in contrast to reported data concerning intraductal and invasive ductal carcinoma, c-erbB-2 oncogene amplification and/or overexpression does not play a significant role in the progression of lobular breast neoplasia.
小叶原位癌（LCIS）的恶性潜能不确定；人们一直在积极寻找能够识别临床预后不良风险患者的生物标志物。c-erbB-2原癌基因的扩增与浸润性乳腺癌的预后不良相关，对癌基因蛋白表达的免疫组化评估与基因扩增相关。作者回顾性评估了62例小叶肿瘤，采用抗生物素蛋白-生物素-过氧化物酶法，使用两种抗erbB-2（p185）单克隆抗体（c-neu Ab3和m-erb）和一种抗erbB-2多克隆抗体（pAb 1），在福尔马林固定、脱石蜡切片上检测c-erbB-2基因产物的表达。所有62例病例用pAb 1抗体检测均为阴性；62例中有1例用c-neu Ab3呈膜状弱阳性。1例在相邻的浸润性导管癌中以及另1例在相邻的导管原位癌中检测到c-erbB-2基因产物的表达。15例浸润性小叶癌中，两种抗c-erbB-2抗体检测均无阳性。1例良性上皮呈强阳性，显示为上皮增生。总之，57例LCIS中有1例检测到c-erbB-2基因产物表达，15例浸润性小叶癌均未检测到。这表明，与关于导管内癌和浸润性导管癌的报道数据相反，c-erbB-2癌基因扩增和/或过表达在小叶乳腺肿瘤进展中不起重要作用。
